Trailing-twelve-month (TTM) revenue is $8.51 Billion with a year-over-year growth of +8.62%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $2,001,400,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $2,243,800,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-20 |
| Q1 FY2026Period ended 2026-03-31 | $2,086,700,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-01 |
| Q2 FY2026Period ended 2026-06-30 | $2,177,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $8,508,900,000 |
Current P/S: $18,505,607,610 market capitalization ÷ $8,508,900,000 TTM revenue = 2.17x.
Market capitalization source: FMP quote. Quote observed 2026-09-18T18:15:10.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $2.18B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-18T18:16:17.862Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Hips | $1.8B | $1.9B | $1.9B | $2.0B | $2.0B | $2.1B |
| Knees | $2.4B | $2.6B | $2.8B | $3.0B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Americas | $4.3B | $4.8B | $4.3B | $4.6B | $4.8B | $5.1B |
| Asia Pacific | $1.3B | $1.4B | $1.2B | $1.2B |
$8.51B
$8.51 Billion
+8.62%
vs. $7.83B a year ago (TTM)
+2.89%
5 Year compound annual growth rate
1 Year
+8.62%
3 Year
+5.75%
5 Year
+2.89%
10 Year
+1.22%
15 Year
+4.57%
20 Year
+4.77%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $8.23B | +$552.90M | +7.20% |
| 2024 | $7.68B | +$284.40M | +3.85% |
| 2023 | $7.39B | +$454.30M | +6.55% |
| 2022 | $6.94B | +$112.60M | +1.65% |
| 2021 | $6.83B | +$699.80M | +11.42% |
| 2020 |
TTM Growth
+8.62%
3-Year CAGR
+5.75%
5-Year CAGR
+2.89%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-18T18:16:17.862Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $3.3B |
| Other Product Category | $519M | $596M | $570M | $636M | $640M | N/A |
|---|
| S E T | $1.3B | $1.7B | $1.7B | $1.8B | $1.9B | $2.2B |
|---|
| $1.3B |
| E M E A | $1.4B | $1.7B | $1.5B | $1.6B | $1.7B | $1.8B |
|---|
| $6.13B |
| ($1.85B) |
| (23.24%) |
| 2019 | $7.98B | +$49.30M | +0.62% |
| 2018 | $7.93B | +$129.60M | +1.66% |
| 2017 | $7.80B | +$134.90M | +1.76% |
| 2016 | $7.67B | +$1.67B | +27.85% |
